Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Galena spins-out RXi, which gets $9.5mm in funding from investors

Executive Summary

RXi Pharmaceuticals Corp. is splitting into two publicly traded companies: Galena Biopharma Inc. will focus on cancer therapeutics while the new RXi will spin off and continue the former company’s work on RNAi. In connection with the partial spin-off, two institutional investors purchased $9.5mm of RXi’s Series A preferred shares, an amount which includes shares converted from a $1.5mm bridge loan.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Preliminary
Deal Type
  • Financing
    • Private Investment in Public Biotech
    • Convertible Debt
    • Spin-Off
    • Other
    • Private Placement

Related Companies